Chinook TherapeuticsKDNY
13F holders, Q2 2024 (June 30)2holders +1
1new positions
0sold out
$0.00avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Chinook Therapeutics Inc. (KDNY) in their 13F filings, up 1 from Q1 2024. 1 opened new positions and 0 sold out. The largest holders were Parallel Advisors, LLC ($0) and Farther Finance Advisors, LLC ($0).
- Company
- Chinook Therapeutics Inc.
- CUSIP
- 16961L106
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 100 shares bought, net +100 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Parallel Advisors, LLC | 0.00% | No change | 5 | $0 |
| Farther Finance Advisors, LLC | 0.00% | New | 100 | $0 |
"% of holder's portfolio" is KDNY's weight in each manager's 13F, not the share of Chinook Therapeutics Inc. the manager owns.